Meeting
2022 ASCO Annual Meeting
Factors associated with short- and long-term survival in metastatic HER2+ breast cancer.
Authors
Jose Pablo Leone
Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA
Jose Pablo Leone , Julieta Leone , Carlos Teodoro Vallejo , Heather Anne Parsons , Michael J. Hassett , Nancy U. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1047)
DOI
10.1200/JCO.2022.40.16_suppl.1047
Abstract #
1047
Poster Bd #
425
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
First Author: Giuseppe Curigliano
Poster
2023 ASCO Annual Meeting
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.
First Author: Erika P. Hamilton
Poster
2023 ASCO Annual Meeting
HER2-low breast cancer brain metastases: Incidence and treatment implications.
First Author: Rania Chehade
Poster
2022 ASCO Annual Meeting
Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
First Author: Ian E. Krop